MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells

Cao,Jian; Liu,Jun; Xu,Ran; Zhu,Xuan; Liu,Lei; Zhao,Xiaokun

doi:10.3892/mmr.2015.4568

MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells

Authors:
- Jian Cao
- Jun Liu
- Ran Xu
- Xuan Zhu
- Lei Liu
- Xiaokun Zhao
View Affiliations

Affiliations: Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Urology, The Fifth Teaching Hospital of Xinjiang Medical University, Wulumuqi, Xinjiang 830011, P.R. China
Published online on: November 13, 2015 https://doi.org/10.3892/mmr.2015.4568
Pages: 75-82
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clear cell renal cell carcinoma (ccRCC) metastasis may result from epithelial-to-mesenchymal transition and mesenchymal stem cells that contribute to the development of the primary tumor. In this study, it was demonstrated that microRNA-21 (miR-21) acts as an oncogenic driver of ccRCC. ccRCC spheres were isolated and it was shown that they exhibited cancer stem cell‑like properties, including the formation of self‑renewing spheres. Spheres showed increased expression of stem cell‑related transcription factors and epithelial‑mesenchymal transition (EMT) markers. In addition, secondary sphere formation capacity was assessed after miR‑21 transfection. miR‑21 accelerated the formation of ccRCC spheres, which shared molecular characteristics with the spontaneous ccRCC spheres. It was demonstrated that miR‑21 overexpression facilitates ccRCC sphere formation. Thus, a single miRNA may have an impact on the formation of highly tumorigenic cancer spheres in kidney cancer.

View Figures

View References

1	Chow WH, Dong LM and Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
2	Azeem K, Kollarova H, Horakova D, Magnuskova S and Janout V: Genetic syndromes associated with renal cell carcinoma: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 155:231–238. 2011. View Article : Google Scholar
3	Novick AC: Kidney cancer: Past, present and future. Urol Oncol. 25:188–195. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Yi Z, Fu Y, Zhao S, Zhang X and Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862. 2010. View Article : Google Scholar
7	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
8	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
9	Prud'homme GJ: Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des. 18:2838–2849. 2012. View Article : Google Scholar : PubMed/NCBI
10	Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X and Wu C: Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Med Biochem. 363:427–436. 2012.
11	Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA and Ellis LM: Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 1:5–16. 2012. View Article : Google Scholar
12	Kanzawa M, Semba S, Hara S, Itoh T and Yokozaki H: WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology : journal of immunopathology, molecular and cellular biology. 80:235–244. 2013. View Article : Google Scholar
13	Luo Y, Cui XH, Jiang YG, et al: Epithelial-mesenchymal transition of prostate cancer: cancer stem cells or bulk cancer cells. Zhonghua yi xue za zhi. 93:256–260. 2013.PubMed/NCBI
14	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
15	Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 5:744–749. 2005. View Article : Google Scholar : PubMed/NCBI
16	Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K and Diamandis EP: Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer. 88:1101–1104. 2003. View Article : Google Scholar : PubMed/NCBI
17	Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I and Hampson G: Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol. 177:423–433. 2003. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Bera A, Das F, Ghosh-Choudhury N, Kasinath BS, Abboud HE and Choudhury GG: MicroRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res. 328:99–117. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP and Ramkumar V: Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One. 7:e516552012. View Article : Google Scholar : PubMed/NCBI
21	Bornachea O, Santos M, Martinez-Cruz AB, García-Escudero R, Dueñas M, Costa C, Segrelles C, Lorz C, Buitrago A, Saiz-Ladera C, et al: EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep. 2:4342012. View Article : Google Scholar : PubMed/NCBI
22	Huang B, Huang YJ, Yao ZJ, Chen X, Guo SJ, Mao XP, Wang DH, Chen JX and Qiu SP: Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS One. 8:e682932013. View Article : Google Scholar : PubMed/NCBI
23	Lichner Z, Saleh C, Subramaniam V, Seivwright A, Prud'homme GJ and Yousef GM: MiR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties. Oncotarget. 6:5567–5581. 2015. View Article : Google Scholar :
24	Li L, Zhou L, Li Y, Lin S and Tomuleasa C: MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. J Buon. 19:228–236. 2014.PubMed/NCBI
25	Selcuklu SD, Donoghue MT and Spillane C: MiR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 37:918–925. 2009. View Article : Google Scholar : PubMed/NCBI
26	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Prco Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar
27	Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sültmann H: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 128:608–616. 2011. View Article : Google Scholar
28	Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH and Ye DW: Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 71:326–331. 2011. View Article : Google Scholar
29	Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P and Blelloch R: Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71:550–560. 2011. View Article : Google Scholar :
30	Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y and Dahiya R: Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 17:5287–5298. 2011. View Article : Google Scholar
31	Collyer TC, Yates DR and Bellamy MC: Severe air embolism resulting from a perforated cap on a high-flow three-way stopcock connected to a central venous catheter. Eur J Anaesthesiol. 24:474–475. 2007. View Article : Google Scholar : PubMed/NCBI
32	Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R, et al: The application of artificial intelligence to microarray data: Identification of a novel gene signature to identify bladder cancer progression. Eur Urol. 57:398–406. 2010. View Article : Google Scholar
33	Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D and Summerhayes IC: A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol. 28:39–48. 2010. View Article : Google Scholar
34	Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al: Identifying mRNA targets of microRNA dysregulated in cancer: With application to clear cell renal cell carcinoma. BMC Syst Biol. 4:512010. View Article : Google Scholar : PubMed/NCBI
35	Liu W, Zabirnyk O, Wang H, Shiao YH, Nickerson ML, Khalil S, Anderson LM, Perantoni AO and Phang JM: miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 29:4914–4924. 2010. View Article : Google Scholar : PubMed/NCBI
36	Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder and kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
37	Baker M: Cancer stem cells tracked. Nature. 488:13–14. 2012. View Article : Google Scholar : PubMed/NCBI
38	Blagosklonny MV: Target for cancer therapy: Proliferating cells or stem cells. Leukemia. 20:385–391. 2006. View Article : Google Scholar